Shi Wei M.D., Ph.D.

Shi Wei M.D., Ph.D.
Professor

Senior Scientist, Experimental Therapeutics , O'Neal Comprehensive Cancer Center
Professor (P), Anatomic Pathology , Clinical Pathology 2009 -
Scientist (C), Comprehensive Arthritis, Musculoskeletal, Bone and Autoimmunity Center (CAMBAC) , School of Medicine 2015 -
Senior Scientist (C), O'Neal Comprehensive Cancer Center , School of Medicine 2017 -

Overview

Dr. Wei obtained his M.D. from China Medical University (Shenyang, China) and received his Ph.D. from Okayama University in Japan. He completed a post-doctoral fellowship at Washington University School of Medicine (St. Louis, Missouri) prior to coming to UAB, where he finished his pathology residency followed by a surgical pathology fellowship. He obtained additional clinical subspecialty training at Emory, Mt. Sinai and Harvard Universities. Dr. Wei is board certified in Anatomic and Clinical Pathology. He joined the faculty at UAB in July, 2008 and is currently a Tenured Professor. Dr. Wei heads the Surgical Pathology Section at the Division of Anatomic Pathology, Department of Pathology, and directs the Surgical Pathology Fellowship Program.

Selected Publications

Academic Article

Year	Title	Altmetric
2021	Validation of the revised 8th AJCC breast cancer clinical prognostic staging system: analysis of 5321 cases from a single institution. Modern Pathology. 34:291-299. 2021
2020	Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution. Modern Pathology. 33:2499-2506. 2020
2020	Rare MDM2 amplification in a fat-predominant angiomyolipoma 2020
2020	Clear cell papillary neoplasm of the breast with MAML2 gene rearrangement: Clear cell hidradenoma or low-grade mucoepidermoid carcinoma? 2020
2020	RANKLed by the Complexity of Signaling in Breast Cancer Metastasis to the Brain. Clinical Breast Cancer. 20:e569-e575. 2020
2020	Association of Event-Free and Distant Recurrence-Free Survival with Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncology. 6:1355-1362. 2020
2020	Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. Modern Pathology. 33:1746-1752. 2020
2020	PGC1α suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression 2020
2020	PRDM16 suppresses HIF-targeted gene expression in kidney cancer. Journal of Experimental Medicine. 217. 2020
2020	A CD24-p53 axis contributes to African American prostate cancer disparities 2020
2020	Histone-induced thrombotic thrombocytopenic purpura in adamts13^-/- zebrafish depends on von Willebrand factor 2020
2020	The nad-dependent deacetylase SIRT2 regulates T cell differentiation involved in tumor immune response. International Journal of Biological Sciences. 16:3075-3084. 2020
2019	Synchronous and metachronous bilateral breast cancer: clinicopathologic characteristics and prognostic outcomes. Human Pathology. 92:1-9. 2019
2019	Autophagy-related 7 modulates tumor progression in triple-negative breast cancer. Laboratory Investigation. 99:1266-1274. 2019
2019	Bone Pathology for Hematopathologists. Surgical Pathology Clinics. 12:831-847. 2019
2019	Inflammatory myofibroblastic tumor of bone harboring an ALK gene amplification 2019
2019	PAX8 Expression in Solitary Fibrous Tumor: A Potential Diagnostic Pitfall. Applied Immunohistochemistry and Molecular Morphology. 27:195-202. 2019
2019	Inhibition of heme oxygenase-1 enhances hyperthermia-induced autophagy and antiviral effect. International Journal of Biological Sciences. 15:568-578. 2019
2019	Loss of FOXP3 and TSC1 accelerates prostate cancer progression through synergistic transcriptional and posttranslational regulation of c-Myc. Cancer Research. 79:1413-1425. 2019
2018	Comparison of AJCC Anatomic and Clinical Prognostic Stage Groups in Breast Cancer: Analysis of 3322 Cases From a Single Institution. Clinical Breast Cancer. 18:e1347-e1352. 2018
2018	The neutrophil chemoattractant peptide proline-glycine-proline is associated with acute respiratory distress syndrome 2018
2018	Clinicopathologic Features and Clinical Outcome Differences in De Novo Versus Secondary Histiocytic Sarcomas: A Multi-institutional Experience and Review of the Literature. Clinical Lymphoma, Myeloma and Leukemia. 18:e427-e435. 2018
2018	Chondroblastoma-like tumor of the skull in a patient with cardio-facio-cutaneous syndrome 2018
2018	Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets. European urology focus. 4:733-736. 2018
2018	Phosphorylation of SMC1A promotes hepatocellular carcinoma cell proliferation and migration. International Journal of Biological Sciences. 14:1081-1089. 2018
2018	Conditional knockout of N-Myc and STAT interactor disrupts normal mammary development and enhances metastatic ability of mammary tumors. Oncogene. 37:1610-1623. 2018
2018	Surviving at a distant site: The organotropism of metastatic breast cancer. Seminars in Diagnostic Pathology. 35:108-111. 2018
2017	Prognostic outcomes in advanced breast cancer: the metastasis-free interval is important. Human Pathology. 70:70-76. 2017
2017	Clinical and pathological factors related to brain relapse-free survival in breast cancer patients—reply. Human Pathology. 69:142. 2017
2017	Corrigendum to “Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone” (Human Pathology (2017) 65 (239–246) (S0046817717301727) (10.1016/j.humpath.2017.05.015)). Human Pathology. 69:143. 2017
2017	Extraskeletal aneurysmal bone cyst: Report of a case and review of the literature 2017
2017	The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer. Human Pathology. 69:110-117. 2017
2017	Not Your Typical Renal Cyst. American Journal of Medicine. 130:e429-e432. 2017
2017	Carcinoma in situ involving sclerosing adenosis: Seeking the salient histological characteristics to prevent overdiagnosis. Annals of Clinical and Laboratory Science. 47:529-534. 2017
2017	Soft tissue tumor immunohistochemistry update illustrative examples of diagnostic pearls to avoid pitfalls. Archives of Pathology and Laboratory Medicine. 141:1072-1091. 2017
2017	Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone. Human Pathology. 65:239-246. 2017
2017	GATA3 expression in benign prostate glands with radiation atypia: a diagnostic pitfall. Histopathology. 71:150-155. 2017
2017	MicroRNA-200c and microRNA- 141 are regulated by a FOXP3-KAT2B axis and associated with tumor metastasis in breast cancer. Breast Cancer Research. 19. 2017
2017	Clinicopathological factors associated with survival in patients with breast cancer brain metastasis. Human Pathology. 64:53-60. 2017
2017	Reacquisition of E-cadherin expression in metastatic deposits of signet-ring cell carcinoma of the upper gastrointestinal system: A potential anchor for metastatic deposition. Journal of Clinical Pathology. 70:528-532. 2017
2017	Well-Differentiated Laryngeal/Hypopharyngeal Liposarcoma in the MDM2 Era Report of Three Cases and Literature Review. Head and Neck Pathology. 11:146-151. 2017
2017	Let-7 status is crucial for PARP1 expression in HER2-overexpressing breast tumors 2017
2017	DNA-PkCS expression in oropharyngeal squamous cell carcinoma: Correlations with human papillomavirus status and recurrence after transoral robotic surgery 2017
2017	Differential gene expression in ductal carcinoma in situ of the breast based on ERBB2 status. Cancer Control : Journal of the Moffitt Cancer Center. 24:102-110. 2017
2017	Metastatic organotropism: An intrinsic property of breast cancer molecular subtypes. Advances in Anatomic Pathology. 24:78-81. 2017
2017	Primary Renal Ewing Sarcoma in an Adult. Urology. 99:e11-e13. 2017
2017	Reduced E-Cadherin and Aberrant β-Catenin Expression are Associated with Advanced Disease in Signet-Ring Cell Carcinomas. Applied Immunohistochemistry and Molecular Morphology. 25:432-438. 2017
2016	Clinicopathologic factors associated with de novo metastatic breast cancer 2016
2016	Notch signaling activation is associated with patient mortality and increased FGF1-mediated invasion in squamous cell carcinoma of the oral cavity 2016
2016	Kinase gene expression profiling of metastatic clear cell renal cell carcinoma tissue identifies potential new therapeutic targets. PLoS ONE. 11. 2016
2016	Papillary lesions of the breast an update. Archives of Pathology and Laboratory Medicine. 140:628-643. 2016
2016	Silencing of CD24 enhances the PRIMA-1-induced restoration of mutant p53 in prostate cancer cells. Clinical Cancer Research. 22:2545-2554. 2016
2016	Gorham-stout disease successfully treated with sirolimus and zoledronic acid therapy. Journal of Pediatric Hematology/Oncology. 38:e129-e132. 2016
2016	Prognostic factors in advanced breast cancer: Race and receptor status are significant after development of metastasis 2016
2016	Prognostic value of E-cadherin and β-catenin in triple-negative breast cancer. American Journal of Clinical Pathology. 146:603-610. 2016
2016	Protective effect of suppressing STAT3 activity in LPS-induced acute lung injury 2016
2016	The rank pathway in advanced breast cancer: Does Src play a role?. Applied Immunohistochemistry and Molecular Morphology. 24:42-50. 2016
2015	Characterization of estrogen receptor-negative/progesterone receptor-positive breast cancer. Human Pathology. 46:1776-1784. 2015
2015	Sinonasal renal cell-like adenocarcinomas: Robust carbonic anhydrase expression. Human Pathology. 46:1598-1606. 2015
2015	Effect of African-American Race on Tumor Recurrence after Radical Cystectomy for Urothelial Carcinoma of the Bladder. Clinical Genitourinary Cancer. 13:469-475. 2015
2015	Solitary, adult-onset, intraosseous myofibroma of the finger: report of a case and review of literature. Hand. 10:550-554. 2015
2015	The IVVY motif and tumor necrosis factor receptor-associated factor (TRAF) sites in the cytoplasmic domain of the receptor activator of nuclear factor κB (RANK) cooperate to induce osteoclastogenesis. Journal of Biological Chemistry. 290:23738-23750. 2015
2015	Mammary analog secretory carcinoma, low-grade salivary duct carcinoma, and mimickers: A comparative study. Modern Pathology. 28:1084-1100. 2015
2015	FOXP3-MIR-146-NF-κB axis and therapy for precancerous lesions in prostate. Cancer Research. 75:1714-1724. 2015
2015	PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers. Breast Cancer Research and Treatment. 150:569-579. 2015
2015	Composite encapsulated papillary carcinoma and solid papillary carcinoma. Pathology International. 65:133-137. 2015
2015	Breast cancer subtypes predispose the site of distant metastases. American Journal of Clinical Pathology. 143:471-478. 2015
2015	Florid reactive periostitis ossificans of the humerus: Case report and differential diagnosis of periosteal lesions of long bones. World Journal of Orthopedics. 6:559-563. 2015
2015	GATA3 expression in advanced breast cancer: Prognostic value and organ-specific relapse. American Journal of Clinical Pathology. 144:756-763. 2015
2015	The utility of phosphohistone H3 in breast cancer grading. Applied Immunohistochemistry and Molecular Morphology. 23:689-695. 2015
2014	An extremely rare primary gallbladder myxoid liposarcoma associated with amplification of DDIT3 gene. Journal of Gastrointestinal and Liver Diseases. 23:460-461. 2014
2014	Envisioning the Next WHO Head and Neck Classification. Head and Neck Pathology. 8:1-15. 2014
2014	Breast implant-associated anaplastic large cell lymphoma: Review of a distinct clinicopathologic entity. Archives of Pathology and Laboratory Medicine. 138:842-846. 2014
2014	Changing prognostic factors in osteosarcoma: Analysis of 381 cases from two institutions. Human Pathology. 45:1688-1696. 2014
2014	Characteristics of breast carcinoma cases with false-negative sentinel lymph nodes. Clinical Breast Cancer. 14:280-284. 2014
2014	L-2-hydroxyglutarate: An epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discovery. 4:1290-1298. 2014
2014	Optimal handling of bone tumor specimens. Methods in Molecular Biology. 1180:353-368. 2014
2014	Prognostic factors in patients with metastatic breast cancer at the time of diagnosis 2014
2014	Round cell tumors of bone: An update on recent molecular genetic advances. Advances in Anatomic Pathology. 21:359-372. 2014
2013	Syndecan-1 overexpression is associated with nonluminal subtypes and poor prognosis in advanced breast cancer. American Journal of Clinical Pathology. 140:468-474. 2013
2013	Immunohistochemical studies of metastatic germ-cell tumors in retroperitoneal dissection specimens: A sensitive and specific panel. International Journal of Surgical Pathology. 21:342-351. 2013
2013	Expression of SALL4 and SF-1 in gonadoblastoma: Useful markers in the identification of the invasive germ cell component 2013
2013	Microsatellite instability and TARBP2 mutation study in upper urinary tract urothelial carcinoma. American Journal of Clinical Pathology. 139:765-770. 2013
2013	Sclerosing epithelioid fibrosarcoma of the pancreas. Annals of Diagnostic Pathology. 17:214-216. 2013
2013	AIRP best cases in radiologic-pathologic correlation: Gallbladder carcinoma with direct invasion of the liver. Radiographics. 33:103-108. 2013
2013	SALL4 and SF-1 are sensitive and specific markers for distinguishing granulosa cell tumors from yolk sac tumors. International Journal of Surgical Pathology. 21:121-125. 2013
2012	Factors associated with residual disease after initial breast-conserving surgery for ductal carcinoma in situ. Human Pathology. 43:986-993. 2012
2012	A novel t(6;13)(q15;q34) translocation in a giant cell reparative granuloma (solid aneurysmal bone cyst). Human Pathology. 43:952-957. 2012
2012	Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis. Journal of Biological Chemistry. 287:15728-15738. 2012
2012	CD138 (syndecan-1) expression in bone-forming tumors. American Journal of Clinical Pathology. 137:423-428. 2012
2012	Complex analysis of a recurrent pleomorphic hyalinizing angiectatic tumor of soft parts. Human Pathology. 43:121-126. 2012
2012	Molecular mechanisms of the biphasic effects of interferon-γ on osteoclastogenesis. Journal of Interferon and Cytokine Research. 32:34-45. 2012
2011	A 23-year-old woman with a right femoral neck fracture 2011
2011	Composite cutaneous atypical vascular lesion and Langerhans cell histiocytosis after radiation for breast carcinoma: Can radiation induce Langerhans cell histiocytosis?. Dermatology Online Journal. 17. 2011
2011	Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: A novel mechanism mediating its blockade of osteoclastogenesis. Journal of Cellular Biochemistry. 112:3385-3392. 2011
2011	Primary Leiomyosarcoma of the Inferior Vena Cava Invading the Right Atrium: A Technique for Intraluminal Biopsy Through a Transvenous Approach. Vascular and Endovascular Surgery. 45:743-746. 2011
2011	Renal cell carcinoma metastasizing to solitary fibrous tumor of the pleura: A case report. Journal of Medical Case Reports. 5. 2011
2011	Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organs. Annals of Diagnostic Pathology. 15:79-83. 2011
2010	Juxtatumoral stromal reactions in uterine endometrioid adenocarcinoma and their prognostic significance 2010
2009	Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: A tissue microarray and pooled literature review study. Applied Immunohistochemistry and Molecular Morphology. 17:393-402. 2009
2008	Sinonasal teratocarcinosarcoma: report of a case with review of literature and treatment outcome. Annals of Diagnostic Pathology. 12:415-425. 2008
2008	Mechanisms modulating inflammatory osteolysis: A review with insights into therapeutic targets 2008
2008	Targeting p38 MAPK for the treatment of inflammatory arthritis. Future Rheumatology. 3:37-42. 2008
2007	p38 MAPK as a potential therapeutic target for inflammatory osteolysis. Advances in Anatomic Pathology. 14:42-45. 2007
2005	Receptor activator of NF-κB (RANK) cytoplasmic motif, ³⁶⁹PFQEP³⁷³, plays a predominant role in osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4. Journal of Biological Chemistry. 280:43064-43072. 2005
2005	IL-1 mediates TNF-induced osteoclastogenesis. Journal of Clinical Investigation. 115:282-290. 2005
2004	Marrow stromal cells and osteoclast precursors differentially contribute to TNF-α-induced osteoclastogenesis in vivo. Journal of Immunology. 173:4838-4846. 2004
2004	The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. Journal of Clinical Investigation. 114:206-213. 2004
2002	Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and function. Endocrinology. 143:4868-4874. 2002
2002	Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-κB and mitogen-activated protein kinase signaling. Journal of Biological Chemistry. 277:6622-6630. 2002
2001	Receptor activator of nuclear factor-κB ligand activates nuclear factor-κB in osteoclast precursors. Endocrinology. 142:1290-1295. 2001
2000	Tumor necrosis factor α regulates αvβ5 integrin expression by osteoclast precursors in vitro and in vivo. Endocrinology. 141:284-290. 2000

Book

Year	Title	Altmetric
2015	Advances in surgical pathology: Breast cancer 2015

Chapter

Year	Title	Altmetric
2015	Molecular pathology of osteosarcoma. 213-222. 2015
2014	Benign Tumors and Tumor-Like Conditions of Bone. 838-855. 2014
2014	MaLignant Tumors of Bone. 856-873. 2014

Research Overview

Dr. Wei is actively engaged in the diagnostic surgical pathology service and has special interests in breast, muskuloskeletal and genitourinary pathology. His major research interests include discovery and evaluation of biomarkers in breast cancer and other malignancies, evaluation of prognostic factors in breast cancer and malignant bone tumors, and tumor bone metastasis. He has published more than a hundred manuscripts in these areas in some of the leading peer-reviewed journals, of which he first- or senior-authored approximately two-thirds. Dr. Wei is a Senior Scientist at UAB Comprehensive Cancer Center, Experimental Therapeutics Program. He co-directs the Pathology Research Core Laboratory.

Keywords: Breast Pathology; Muskuloskeletal Pathology; Genitourinary Pathology